Company Description
Kailera Therapeutics is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey.
We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration.
Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better.
| Country | United States |
| Founded | 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
| CEO | Ronald C. Renaud, Jr. |
Contact Details
Address: 180 Third Avenue, 4th Floor Waltham, MA 02451 United States | |
| Phone | (781) 317-0290 |
| Website | kailera.com |
Stock Details
| Ticker Symbol | KLRA |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 2096997 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ronald C. Renaud, Jr. | President, Chief Executive Officer and Director |
| Scott Akamine | Chief Legal Officer and Secretary |
| Paul Burgess | Chief Operating Officer and Chief Business Officer |
| Paula Cloghessy | Chief People Officer |
| Jamie Coleman | Chief Commercial Officer |
| Douglas Pagán | Chief Financial Officer |
| Scott Wasserman, M.D. | Chief Medical Officer |
| John F. Milligan, Ph.D. | Chairman |
| Frank Clyburn, Jr. | Director |
| Michael Gladstone | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 11, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 19, 2025 | DRS | [Cover] Draft Registration Statement |